Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging
暂无分享,去创建一个
[1] S. Aalto,et al. Striatal subregional 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease: A two‐year follow‐up study , 2006, Movement disorders : official journal of the Movement Disorder Society.
[2] P. Stanzione,et al. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study , 2006, Nuclear medicine communications.
[3] Orazio Schillaci,et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms , 2005, Nuclear medicine communications.
[4] P. M. Kemp,et al. Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and Lewy body dementia , 2005, Nuclear medicine communications.
[5] P. Morrish. The meaning of negative DAT SPECT and F‐Dopa PET scans in patients with clinical Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[6] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[7] E. Tolosa,et al. Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes , 2004, Movement disorders : official journal of the Movement Disorder Society.
[8] David Oakes,et al. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. , 2004, Archives of neurology.
[9] Regina Katzenschlager,et al. Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders , 2003, Movement disorders : official journal of the Movement Disorder Society.
[10] Oliver Pogarell,et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3‐month observations , 2003, Movement disorders : official journal of the Movement Disorder Society.
[11] Claude Nahmias,et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.
[12] J. C. Stoof,et al. [123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.
[13] L. Friberg,et al. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Z Walker,et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand , 2002, Journal of neurology, neurosurgery, and psychiatry.
[15] J. Seibyl,et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.
[16] Andrew J. Lees,et al. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.
[17] H. Berendse,et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell , 2001, Annals of neurology.
[18] Jan Booij,et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.
[19] N. Quinn,et al. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism , 2000, Neurology.
[20] D J Wyper,et al. Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.
[21] J. Rinne,et al. Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT , 2000, Annals of neurology.
[22] S. Gacinovic,et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.
[23] J. Jankovic,et al. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. , 2000, Archives of neurology.
[24] P. Hobson,et al. Accuracy of diagnosis in patients with presumed Parkinson's disease. , 1999, Age and ageing.
[25] J. P. Seibyl,et al. [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease , 1996, Neurology.
[26] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[27] W. Gibb,et al. THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE , 1989, Neuropathology and applied neurobiology.
[28] J. Talairach,et al. Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .
[29] J. Booij,et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease , 2005, European Journal of Nuclear Medicine.
[30] Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.
[31] J. Booij,et al. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease , 2001, Journal of Neural Transmission.